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Is it the low-protein diet or simply 
the salt restriction?
MR Weir1
Dietary factors, such as salt and protein intake, may play an 
important role in the progression of kidney disease. Consequently, 
dietary manipulations of these constituents are of interest both in 
experimental models of kidney disease and in clinical trials with 
patients with chronic kidney disease to assess whether modification 
of these exposures will result in a stabilization of disease progression.
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Chronic kidney disease (CKD) is a more 
common clinical problem that once 
thought and is frequently associated 
with substantial cardiovascular morbid-
ity and mortality. It is well recognized 
that better control of blood pressure is 
important in mitigating the progression 
of CKD. In addition, pharmacological 
manipulation of the renin–angiotensin 
system plays an important role as part 
of an eff ective blood pressure-lowering 
strategy in reducing the rate of progres-
sion of kidney disease. It is also recog-
nized that dietary factors may also be 
important in the rate of progression of 
kidney disease.1 Both dietary protein 
and salt have been implicated as targets 
for manipulation to limit progression of 
kidney disease.
When the Modification of Diet in 
Renal Disease study was completed 
more than a decade ago, it was assumed 
that blood pressure, and not intensive 
dietary protein restriction, was the criti-
cal factor in limiting the progression of 
kidney disease.2 However, it is impor-
tant to note that in the Modifi cation of 
Diet in Renal Disease study the major-
ity of patients received angiotensin-
converting enzyme  inhibitors and 
calcium channel blockers, achieved 
the respective target blood pressure 
goals, and had intensive dietary edu-
cation to achieve a daily salt intake of 
approximately 1 g. It is quite likely that 
improved blood pressure control, angi-
otensin-converting enzyme inhibition, 
and dietary salt restriction mitigated 
the potential benefi ts of a very-low-pro-
tein diet in delaying the progression of 
kidney disease. Moreover, the trial design 
did not use a washout period to remove 
from the analysis the initial hemody-
namic decrease of glomerular fi ltration 
rate in response to the reduction of pro-
tein intake. It is also important to note 
that reduction in dietary protein can 
reduce glomerular fi ltration rate, hyper-
fi ltration, and proteinuria, which could 
be helpful in mitigating the progression 
of kidney disease. I suspect that more 
eff ort has not been focused on dietary 
protein restriction because of concerns 
about impairing nutrition, which is par-
ticularly important in patients with more 
advanced kidney disease, and problems 
of cost and compliance with specialized 
lower-protein diets.
In an interesting paper, Bellizzi et al.3 
(this issue) report their evaluation of 
a very-low-protein diet supplemented 
with ketoanalogs in patients with stage 4 
and stage 5 kidney disease. Th is study 
is reminiscent of the Modifi cation of 
Diet in Renal Disease study and incor-
porated the same types of patients with 
more advanced forms of kidney disease. 
Th e authors clearly demonstrate that 
those patients on the very-low-protein 
diet achieved a statistically signifi cant 
reduction of blood pressure despite 
concurrent reduction in antihyperten-
sive medication. Moreover, they dem-
onstrate that urine urea correlated with 
reduced urinary sodium excretion and 
that blood pressure reduction was inde-
pendently related to urinary sodium 
excretion and the very-low-protein diet 
restriction, but not the level of protein 
intake. Th eir working hypothesis with 
these results raised the question of why 
the very-low-protein diet was eff ective 
in reducing the blood pressure. Was it 
simply reduced dietary sodium intake, 
or the type of vegetable proteins in the 
very-low-protein diet, or the ketoanalog 
supplementation, which could provide 
a vasodilator eff ect of branched-chain 
essential amino acids? Although the 
authors are fair in providing a bal-
anced perspective in this regard, I fi nd 
it quite likely that the majority of the 
effects are related simply to reduced 
dietary salt exposure. The authors 
importantly noted that there was a cor-
relation between decreased fractional 
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excretion of sodium, stability of glomer-
ular filtration rate, and decreased 
sodium intake, which leads one to 
the conclusion that there was associ-
ated subtle volume contraction, which 
is likely to be important in reducing 
blood pressure in people with CKD. 
Th is makes far more sense than consid-
ering that the types of vegetable proteins 
or ketoanalog supplementation would 
have a blood pressure-lowering eff ect. 
Interestingly, Bellizzi et al.3 also showed 
that there is no evidence of increased 
urinary potassium excretion to explain 
the vasodepressor responses with a very-
low-protein diet. Diminished potas-
sium intake in the setting of increased 
sodium intake has been hypothesized as 
a potential factor in leading to higher 
levels of blood pressure. However, this 
study is not conclusive in suggesting that 
potassium intake is not involved in the 
regulation of blood pressure; perhaps it 
is just less important in people who are 
already sodium restricted.
Why might salt intake be such an 
important modifi er of the rate of pro-
gression of kidney disease? Th ere are 
both hemodynamic considerations 
(high levels of blood pressure) and non-
hemodynamic considerations that have 
been debated in the literature.4,5 Cer-
tainly patients with CKD appear to be 
more blood pressure salt sensitive. Th us, 
increasing amounts of dietary salt could 
exaggerate (or elevate) the blood pres-
sure. On the other hand, dietary sodium 
avoidance may have a more robust 
impact in reducing blood pressure in 
patients with CKD. Bellizzi et al.3 dem-
onstrated that reducing dietary salt by 
3 g resulted in a blood pressure reduc-
tion of about 8–9 mm Hg. Similarly, 
clinical studies illustrate that increasing 
dietary salt off sets both the antihyper-
tensive and the antiproteinuric eff ects of 
drugs that block the renin–angiotensin 
system.6 This also could impact the 
adequacy of these drugs in stabilizing 
the rate of loss of kidney function over 
time. Th ere is also clinical evidence of 
altered glomerular hemodynamics in 
response to increased dietary salt in 
patients with blood pressure salt sensi-
tivity, which could predispose to pro-
gressive kidney disease in that greater 
levels of glomerular capillary pressure 
and proteinuria could indicate increased 
hydraulic stress with increased risk for 
glomerular injury.7
Th ere are also experimental obser-
vations linking salt exposure to tissue 
injury. Sanders8 has demonstrated that 
increasing salt intake in experimen-
tal animals results in increased intra-
kidney levels of transforming growth 
factor-β, which may result in stimu-
lation of matrix protein production 
and deposition. Likewise, others have 
linked increased salt consumption in 
experimental animals with increased 
reactive oxygen species production both 
in vascular beds and in the renal cor-
tex.9 It is hypothesized that an unfavo-
rable balance of reactive oxygen species 
and increased production of oxida-
tive stress markers may lead to kidney 
tissue injury.
In summary, the observations of 
Bellizzi and colleagues3 that a very-
low-protein diet supplemented with 
ketoanalogs improves blood pressure 
control in patients with CKD are impor-
tant in that one of the main modifi ers 
of the rate of progression of kidney 
disease, blood pressure, can be aff ected 
by dietary manipulation. One cannot 
rule out an additional benefit of the 
lower-protein diet, or the ketoanalog 
supplementation. I suspect that the real 
advantage is modifi cation of salt intake. 
Moreover, there is suffi  cient evidence in 
the literature to indicate that dietary salt 
may be a modifi able risk factor for the 
progression of kidney disease, whether 
one considers the hemodynamic or 
the non-hemodynamic eff ects. Future 
clinical trials will need to more care-
fully evaluate the relationship between 
dietary salt and CKD progression.10 A 
conceptual framework for evidence is 
outlined in Figure 1. Until clinical tri-
als demonstrate whether or not specifi c 
alterations in dietary electrolytes are 
important in delaying progression of 
kidney disease, it is important to con-
sider modest dietary avoidance of salt 
in patients with CKD, particularly if 
they have evidence of hypertension or 
proteinuria.More clinical work needs 
to explore the benefi ts of lower-protein 
diets as part of this eff ort.
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Figure 1 | The interplay between dietary salt, blood pressure, and proteinuria and risk for 
progression to kidney disease.
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Lanthanum carbonate: Time to 
abandon prejudices?
D Brancaccio1 and M Cozzolino1
Since lanthanum carbonate has become available there has been 
much interest in its use as a non-calcium-containing phosphate 
binder, but also much speculation among scientists about possible 
aluminum-like toxicity. This Commentary focuses on the major 
aspects of this scientific controversy, confirming the safety and 
efficacy of this new phosphate binder.
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The crucial role of phosphate in gener-
ating secondary hyperparathyroidism in 
uremic conditions, with its devastating 
clinical consequences for bone disease, 
became evident more than three decades 
ago. More recently, it has also become 
clear that high serum phosphate levels 
are associated with increased mortality, 
a fact that has been supported by large 
epidemiological studies.1 It is now evi-
dent that phosphate overload contri-
butes to accelerated vascular aging, in 
which vascular calcium deposition is a 
key factor.2 Taken together, the conclu-
sions from these major contributions 
to the literature indicate unanimously 
that strict phosphate control in dialysis 
patients should have high priority. How-
ever, reduction of dietary phosphate 
content below 900–1,000 mg per day is 
not clinically achievable and can even 
result in severe malnutrition. Therefore, 
in the large majority of dialysis patients, 
phosphate removal even with a maxi-
mized three-times-per-week dialysis 
schedule is insuffi cient to balance oral 
phosphate intake. The only therapeutic 
tool able to reach a satisfactory phos-
phate control is the use of oral phos-
phate binders.
The story of oral phosphate binders 
started at the beginning of the 1970s 
with the use of aluminum hydroxide, 
a potent phosphate binder that was at 
that time widely used for this purpose in 
dialysis patients and was unfortunately 
also often prescribed to dialysis patients 
as an antacid drug. At that time, the 
knowledge of aluminum toxicity was 
virtually zero among the scientifi c com-
munity. The clinical consequences of its 
use were understood only several years 
later. Anemia, encephalopathy, proxi-
mal myopathy, and osteomalacia repre-
sented rather common features of a slow 
progressive aluminum overload, and 
acute brain derangement leading to 
dementia was more typical of acute 
intoxication, mainly related to contami-
nated dialysis bath.
During the 1980s, calcium carbon-
ate become popular in management of 
phosphate overload in dialysis patients 
because of its combined properties 
(phosphate binding, control of meta-
bolic acidosis, calcium supplementation, 
low cost). Again, many years later, sev-
eral studies revealed the negative impact 
of high intake of calcium carbonate on 
patient survival. Importantly, Goodman 
et al.3 showed that coronary calcifi ca-
tion in dialysis patients was associated 
with increased serum phosphate and 
calcium-phosphate product levels, and 
also with the total daily calcium intake 
from calcium-containing phosphate 
binders, whereas serum calcium levels 
per se were not related to calcifi cation 
score. Several other studies have sup-
ported this concept, and it is now well 
accepted that the overuse of calcium-
containing phosphate binders may 
result in extraskeletal calcifi cation and 
increased cardiovascular mortality.
The third generation of phosphate 
binders was introduced at the beginning 
of the 1990s. Sevelamer hydrochloride 
was the fi rst aluminum- and calcium-
free phosphate binder, containing a 
hydrogel of cross-linked poly(allylamine 
hydrochloride). Sevelamer binds phos-
phate anions through ionic exchange 
with chloride. Treatment of dialysis 
patients with sevelamer, in compari-
son with calcium carbonate, slowed 
down the progression of coronary and 
aortic calcifi cation in a prospective ran-
domized study in which the calcifi cation 
score was assessed in basal conditions 
and after 1 year of treatment.4 In addi-
tion to its phosphate-binding capacity, 
sevelamer also acts as a bile acid seques-
trant, signifi cantly lowering total and 
low-density lipoprotein cholesterol.
More recently, lanthanum carbon-
ate became available as a phosphate 
binder. There has been much enthusi-
asm for this agent, but also much con-
cern among the physicians involved 
in clinical management of  uremic 
patients about potential aluminum-like 
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